Alder Biopharmaceuticals to Present at Two Upcoming Investor ConferencesRandall Schatzman to Deliver Overview of Company at Jefferies Global Life Sciences Conference and Needham Healthcare Conference
BOTHELL, WA – June 7, 2010 – Alder Biopharmaceuticals Inc., announced today that Randall Schatzman, Ph.D., president and chief executive officer, will present at the Jefferies Global Life Sciences Conference and Needham Healthcare Conference in New York City.
The presentation at the Jeffries Global Life Sciences Conference is scheduled for 9 a.m. EDT on Wednesday, June 9. The presentation at the Needham Healthcare Conference is scheduled for 1:20 p.m. EDT on Thursday, June 10.
“This is an exciting time at Alder as we look toward upcoming clinical data announcements for ALD518 in rheumatoid arthritis and cancer,” Schatzman said. “We look forward to meeting with members of the investment community to discuss these programs and our next steps as a company.
Alder Biopharmaceuticals Inc. uniquely identifies, develops and manufactures novel antibody therapeutics to alleviate human suffering in the autoimmune and inflammatory disease areas. Alder’s management team combines decades of industry experience with a proven track record for identifying and developing novel antibody therapeutics and enabling partners through the out-licensing of its technologies. In addition to Bristol-Myers Squibb, partners include Merck (Schering-Plough), Seattle Genetics and Genmab. For more information, visit www.alderbio.com.